プレスリリース

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

プレスリリース

12月. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma

Sebia acquires Zeus Scientific

プレスリリース

10月. 12, 2022

The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity

Sebia and Metafora biosystems form strategic partnership to develop advanced in vitro diagnostics

プレスリリース

9月. 30, 2022

Sebia to acquire a minority stake in Metafora biosystems.

Sebia Acquires Orgentec Diagnostika

プレスリリース

9月. 30, 2022

The strategic acquisition reinforces Sebia’s global leadership in specialty diagnostics.